The PROTAC dBET6, which differs from ARV-825 in its linker system, decreased BRD4 and MYB levels in patient-derived MYB-NFIB and MYB1-NFIB ACC cell lines (SG28 and SG32) and suppressed ACC growth in vitro and in vivo[204]. Here, BRD4 is linked to adrenal cortex carcinoma.